Teunissen, CE;
Verberk, IMW;
Thijssen, EH;
Vermunt, L;
Hansson, O;
Zetterberg, H;
van der Flier, WM;
... Del Campo, M; + view all
(2022)
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.
The Lancet Neurology
, 21
(1)
pp. 66-77.
10.1016/S1474-4422(21)00361-6.
Preview |
Text
Zetterberg_Teunissen.pdf - Accepted Version Download (433kB) | Preview |
Abstract
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
| Type: | Article |
|---|---|
| Title: | Blood-based biomarkers for Alzheimer's disease: towards clinical implementation |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/S1474-4422(21)00361-6 |
| Publisher version: | https://doi.org/10.1016/S1474-4422(21)00361-6 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, FIBRILLARY ACIDIC PROTEIN, FRONTOTEMPORAL LOBAR DEGENERATION, PHOSPHORYLATED TAU 181, NEUROFILAMENT LIGHT, COGNITIVE DECLINE, PLASMA TAU, INDIVIDUALS, PERFORMANCE, DIAGNOSIS, SCIENCE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10141639 |
Archive Staff Only
 |
View Item |
